A normal process called cell competition, in which healthy tissues eliminate unhealthy cells, could be responsible for cancer relapses in patients months or years after they were declared cancer-free
Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment over three weeks instead of five, with comparable tumor control and no increased risk of major complications in wound healing, according to researchers at The University of Texas MD Anderson Cancer Center.
20240208171546.png&width=400&height=400)
Stigma can have profound and lasting effects, and studies have shown that people living with lung cancer may encounter challenges in receiving the support they need from their social network and healthcare providers. Memorial Sloan Kettering Cancer Center (MSK) is committed to helping eliminate the stigmas associated with a lung cancer diagnosis and is working to raise awareness in collaboration with other national organizations.
Patients with cancer and a weakened immune system who are treated with immunotherapies tend to fare far worse from COVID-19 than those who haven't received such therapies in the three months before their COVID diagnosis, show findings in a new study by researchers at Dana-Farber Cancer Institute, and across the U.S., Canada, and Mexico. Researchers found worse outcomes in both the disease itself as well as the fierce immune response that sometimes accompanies it.
A targeted therapy for children with high-risk Hodgkin lymphoma significantly reduced relapse rates, a large multicenter clinical trial conducted by the Children’s Oncology Group shows. The study results have been reported in the New England Journal of Medicine.
A University of Kentucky Markey Cancer Center researcher’s team developed new chemical compounds that show promise as a potential anticancer therapy to treat aggressive tumors. The study led by Samuel G. Awuah, Ph.D., was published in Chemical Communications with Adedamola Arojojoye, a graduate student in Awuah’s lab as the paper’s first author.
The findings, which are the result of single-cell RNA-sequencing, were published in Nature Communications. The research was conducted in the lab of Paula Hurley, PhD, associate professor of Medicine and Urology. The researchers observed an interplay between the inherent properties of cancer cells and microenvironmental factors that contribute to this aggressive subtype of prostate cancer.
Using a novel response-adapted ultra-low dose radiation therapy strategy, MD Anderson researchers observed a 90% complete response rate in patients with orbital indolent B-cell lymphoma. The results were presented today at the 2022 ASTRO Annual Meeting.
A new study may prompt medical experts to rethink when to start mammograms for women who have a mother, sister or daughter diagnosed with breast cancer.
A team of researchers from Mayo Clinic Comprehensive Cancer Center has been awarded a five-year, $12.1 million Specialized Program of Research Excellence (SPORE) grant in breast cancer from the National Cancer Institute (NCI). This is the third renewal of Mayo Clinic's breast cancer SPORE grant.
Two drugs -- one brand new -- reverse pancreatic cell changes that presage one of the hardest cancers to treat. Tested in cells, the drugs would be a promising early cancer treatment if they work in clinical trials.
UTSW study suggests combination therapy might help prostate cancer patients overcome resistance to current treatments
An international team of researchers led by the University of Michigan Rogel Cancer Center received a collaborative SPORE grant from the National Cancer Institute with a goal of bringing new insights into leiomyosarcoma, a rare form of cancer that seemingly originates in smooth muscle.
The National Cancer Institute has awarded a five-year, $13.3 million grant to a collaborative study on sequential combinations of targeted inhibitors and immunotherapies against cancer.
St. Jude scientists have created a tool that can find safe places to put corrected genes into the genome, called safe harbor sites, using genomic and epigenetic information from specific tissue, such as blood cells.
The National Cancer Institute (NCI) has renewed UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center Kidney Cancer Program (KCP) Specialized Program of Research Excellence (SPORE) award. First awarded in 2016, the KCP SPORE is focused on translating discoveries and innovation at UT Southwestern into advances in patient care.
Moffitt Cancer Center has conducted the first prospective study to investigate genomic biomarkers associated with aggressive disease in African American men with prostate cancer. The study results were published in the Journal of the National Cancer Institute.
An extremely common response to cellular stress may be the key to pancreatic cancer in people with obesity, pointing to a new direction for therapy of this difficult-to-treat cancer.
The St. Jude Comprehensive Cancer Center award extends its current $35 million, five-year Cancer Center Support Grant (CCSG) for an additional two years.
Van Andel Institute’s Biorepository has been awarded a $7.9 million, five-year contract from the National Cancer Institute (NCI), part of the National Institutes of Health, to continue serving as the biorepository for the Cancer MoonshotSM Biobank study. The Institute has served as the Cancer MoonshotSM Biobank Biorepository since 2020, when it was awarded a two-year subcontract to develop the framework and protocols for this part of the initiative.
MD Anderson researchers used extensive single-cell analysis to create a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, revealing new roles for these immune cells in cancer development and immunotherapy responses.
Kansas Governor Laura Kelly has proclaimed September “Comprehensive Cancer Centers Awareness Month” in recognition of The University of Kansas Cancer Center becoming designated as a “Comprehensive” cancer center by the National Cancer Institute (NCI).
Scientists at St. Jude Children’s Research Hospital discovered how some cancer cells survive treatment and cause cancer to recur, along with a potential way to stop the process.
Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails. Bispecific antibodies are a type of antibody that can bind to two different antigens at the same time—they are meant to enhance the immune system’s destruction of tumor cells.
New study links men who consumed high rates of ultra-processed foods to a 29% higher risk for developing colorectal cancer than men who consumed much smaller amounts. The team led by researchers from Tufts University and Harvard University did not find the same association in women.
In a new study published in the Proceedings of the National Academy of Sciences (PNAS), Moffitt Cancer Center used mathematical and computer modeling to demonstrate the impact of skin homeostasis on driver and passenger mutations.
In a multinational study led by a Mayo Clinic research team using artificial intelligence (AI), investigators developed an algorithm to improve the prediction of colorectal cancer recurrence. Study results are published in Gastroenterology.
Older adults who participate weekly in many different types of leisure time activities, such as walking for exercise, jogging, swimming laps, or playing tennis, may have a lower risk of death from any cause, as well as death from cardiovascular disease and cancer, according to a new study led by researchers at the National Cancer Institute, part of the National Institutes of Health.
A detailed analysis of pancreatic cancer by researchers at Washington University School of Medicine in St. Louis has revealed details of two key transition points in the development of these tumors — the shift from normal cells to precancerous cells, and the change from precancerous to cancerous cells. Understanding these transitions will help lead to the development of novel therapies.
Aiming to advance the nation’s telehealth research agenda and improve cancer-related care and outcomes, with support from the White House Cancer Moonshot, the Perelman School of Medicine at the University of Pennsylvania is one of four institutions nationally to receive a five-year, $5.7 million grant from the National Cancer Institute (NCI), part of the National Institutes of Health, for a new research center to develop and test advanced methods of telehealth delivery for cancer care with a focus on promoting health equity.
Memorial Sloan Kettering Cancer Center (MSK) today announced it has received a new grant from the National Cancer institute (NCI), part of the National Institutes of Health, under the umbrella of the Cancer Moonshot, to create the MATCHES (Making Telehealth Delivery of Cancer Care at Home Effective and Safe) Telehealth Research Center at MSK, a first of its kind.
Cancer associated fibroblasts in the tumor environment have typically been associated with tumor progression and resistance to therapy, despite some studies suggesting that these fibroblasts may also sensitize cancer cells to therapy. In a new article published in Science Signaling, Moffitt Cancer Center researchers shed light on these conflicting studies and demonstrate that cancer associated fibroblasts can promote or inhibit drug sensitivity based on the type of tumor cell and the drug used for treatment.
In a new University of California, Irvine-led study, researchers define how the circadian clock influences cell growth, metabolism and tumor progression. Their research also reveals how disruption of the circadian clock impacts genome stability and mutations that can further drive critical tumor promoting pathways in the intestine.
The American Society for Radiation Oncology (ASTRO) today expressed its support for President Joseph R. Biden Jr.’s intended appointment of Monica Bertagnolli, MD, as director of the National Cancer Institute (NCI), with the following statement from Laura A. Dawson, MD, FASTRO, Chair of the ASTRO Board of Directors.
UT Southwestern will lead a multisite initiative funded by the National Cancer Institute (NCI) to identify biomarkers to improve risk assessment and early detection of hepatocellular cancer (HCC), the most common form of liver cancer, among patients with cirrhosis.
Studying a deadly type of breast cancer called triple negative, Johns Hopkins Medicine scientists say they have identified key molecular differences between cancer cells that cling to an initial tumor and those that venture off to form distant tumors.
Children’s Hospital of Philadelphia (CHOP) has helped launch a new computational platform that will harmonize pediatric cancer data, allowing researchers, pharmaceutical companies, and advocacy groups to accelerate the pace of drug development for pediatric cancer. With funding from the National Cancer Institute (NCI) via a subcontract with Leidos Biomedical Research, current operator of the NCI’s Frederick National Laboratory for Cancer Research, CHOP researchers have created the Molecular Targets Platform to facilitate pediatric research in response to the Research to Accelerate Cures and Equity (RACE) for Children Act, which requires companies to test cancer drugs in children that are used in adults when there is a shared molecular target.
Data published in Cell Metabolism on liver cancer’s rapid growth which leads to a vulnerability in its energy-production and cell-building processes that may be potently exploited with a new combination-treatment strategy, according to a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.
The National Cancer Institute (NCI) has granted a Merit Extension Award to The Wistar Institute’s Ellen and Ronald Caplan Cancer Center totaling more than $5 million.
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have received a $9.5 million National Cancer Institute Program Project (P01) grant to investigate esophageal adenocarcinoma (EAC), the most common form of esophageal cancer in the United States.
AACI commends the Biden administration on its decision to appoint surgical oncologist Monica Bertagnolli, MD, as the next director of the National Cancer Institute (NCI). Dr. Bertagnolli is the first woman to serve as NCI director.
Cancer cells produce small amounts of their own form of collagen, creating a unique extracellular matrix that affects the tumor microbiome and protects against immune responses, according to a new study by researchers at The University of Texas MD Anderson Cancer Center. This abnormal collagen structure is fundamentally different from normal collagen made in the human body, providing a highly specific target for therapeutic strategies.
Imaging of tissue specimens is an important aspect of translational research that bridges the gap between basic laboratory science and clinical science to improve the understanding of cancer and aid in the development of new therapies. To analyze images to their fullest potential, scientists ideally need an application that enables multiple images to be viewed simultaneously. In an article published in the journal Patterns, Moffitt Cancer Center researchers describe a new open-source software program they developed that allows users to view many multiplexed images simultaneously.
In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased survival relative to historical data and compared favorably to FOLFIRINOX plus hypofractionated radiotherapy, according to research from The University of Texas MD Anderson Cancer Center published today in JAMA Oncology.
An array of new, simple “shelf-available” SARS-CoV-2 treatment options could soon be available in the fight against COVID thanks to a new study, “Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities,” published July 13 in Science Advances.
A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer Center, found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may impact future clinical trials for EGFR exon 20 targeted therapies.
In a new article published in Cancer Research Communications, Moffitt Cancer Center researchers describe the signaling pathways that regulate YAP1 and how the protein contributes to angiogenesis under normal and low oxygen conditions.
Scientists are trying to improve their understanding of the development of clear cell renal cell carcinoma to develop new targeted therapeutics. In a new study published in European Urology, Moffitt Cancer Center researchers identify biomarkers for this disease type and develop a tool to indicate which patients are at high risk of poor outcomes based on their biomarker expression.
The University of Kansas Cancer Center has been designated as a “Comprehensive” cancer center by the National Cancer Institute (NCI). This is the highest level of recognition awarded by the NCI and is the gold standard for cancer centers.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
